| Heart failure
Farxiga vs Kerendia
Side-by-side clinical, coverage, and cost comparison for heart failure.Deep comparison between: Farxiga vs Kerendia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKerendia has a higher rate of injection site reactions vs Farxiga based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kerendia but not Farxiga, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Farxiga
Kerendia
At A Glance
Oral
Once daily
SGLT2 inhibitor
Oral
Once daily
Mineralocorticoid receptor antagonist
Indications
- Chronic Kidney Diseases
- Heart failure
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Chronic kidney disease stage 5
- Myocardial Infarction
Dosing
Chronic Kidney Diseases, Heart failure 10 mg orally once daily.
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg orally once daily; may be increased to 10 mg orally once daily for additional glycemic control. Not recommended when eGFR is less than 45 mL/min/1.73 m2 for glycemic control.
Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg once daily, adjusted after 4 weeks based on serum potassium levels.
Heart failure Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg or 40 mg once daily based on eGFR at initiation, adjusted after 4 weeks.
Contraindications
- Previous serious hypersensitivity reaction to dapagliflozin or any excipient in FARXIGA
- Hypersensitivity to any component of Kerendia
- Concomitant treatment with strong CYP3A4 inhibitors
- Adrenal insufficiency
Adverse Reactions
Most common (>=2%) Female genital mycotic infections, nasopharyngitis, urinary tract infections, back pain, increased urination, male genital mycotic infections, nausea, influenza, dyslipidemia, constipation, discomfort with urination, pain in extremity
Serious Diabetic ketoacidosis, volume depletion, urosepsis and pyelonephritis, hypoglycemia with concomitant insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's Gangrene), hypersensitivity reactions including anaphylaxis and angioedema
Postmarketing Necrotizing fasciitis of the perineum (Fournier's Gangrene), urosepsis and pyelonephritis, ketoacidosis, acute kidney injury, rash
Most common (>=10%) hyperkalemia
Serious hyperkalemia requiring hospitalization, renal impairment, acute kidney injury, renal failure
Postmarketing angioedema, rash, urticaria
Pharmacology
SGLT2 inhibitor; dapagliflozin inhibits sodium-glucose cotransporter 2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion, while also reducing sodium reabsorption to lower cardiac pre- and afterload, suppress sympathetic activity, and decrease intraglomerular pressure via tubuloglomerular feedback.
Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist that blocks MR-mediated sodium reabsorption and MR overactivation in epithelial (kidney) and nonepithelial (heart, blood vessels) tissues; it has high potency and selectivity for the MR with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Farxiga
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
Kerendia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Farxiga
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Kerendia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Farxiga
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Kerendia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Heart Failure - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Bayer US Patient Assistance Foundation - KerendiaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FarxigaView full Farxiga profile
KerendiaView full Kerendia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.